kabutan

ONO PHARMACEUTICAL CO., LTD.(4528) Summary

4528
TSE Prime
ONO PHARMACEUTICAL CO., LTD.
2,315.5
JPY
+9.5
(+0.41%)
May 1, 3:30 pm JST
14.72
USD
May 1, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
16.2
PBR
1.30
Yield
3.45%
Margin Trading Ratio
11.36
Stock Price
May 1, 2026
Opening May 1, 9:00 am
2,287.0 JPY 14.56 USD
Previous Close Apr 30
2,306.0 JPY 14.35 USD
High May 1, 12:52 pm
2,328.0 JPY 14.81 USD
Low May 1, 9:14 am
2,268.5 JPY 14.43 USD
Volume
1,496,900
Trading Value
3.46B JPY 0.02B USD
VWAP
2311.52 JPY 14.7 USD
Minimum Trading Value
231,550 JPY 1,472 USD
Market Cap
1.15T JPY 7.35B USD
Number of Trades
3,646
Liquidity & Number of Trades
As of May 1, 2026
Liquidity
High
1-Year Average
4,027
1-Year High Oct 9, 2025
12,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 43,300 570,400 13.17
Apr 17, 2026 56,900 555,300 9.76
Apr 10, 2026 54,500 549,900 10.09
Apr 3, 2026 57,100 575,600 10.08
Mar 27, 2026 172,100 584,500 3.40
Company Profile
ONO PHARMACEUTICAL CO., LTD. is a mid-tier pharmaceutical company known for its high ratio of in-house developed products, although many are nearing patent expiration. The company is experiencing growth with its new cancer drug "Opdivo".
Sector
Pharmaceuticals
ONO PHARMACEUTICAL CO., LTD. focuses primarily on prescription pharmaceuticals but also produces over-the-counter medications. The company emphasizes research and development, with a strength in innovative in-house products. It operates internationally through subsidiaries engaged in manufacturing, sales, clinical development, and in-licensing/out-licensing activities. The company has sales subsidiaries in Korea and Taiwan, and subsidiaries for clinical development and licensing activities in the United States and the United Kingdom. ONO has achieved significant success with its pioneering cancer immunotherapy drug "Opdivo". The company has also expanded into healthcare-related products, dental supplies, and digital health fields. ONO actively pursues innovation through acquisitions of pharmaceutical startups. The entire group operates under a single business segment of pharmaceuticals.